Pregnenolone

Pregnenolone is a steroid hormone your body makes from cholesterol, and it sits at the very top of the steroid hormone tree. Everything downstream, progesterone, DHEA, testosterone, oestrogen, cortisol, and the brain-active neurosteroid allopregnanolone, gets built from pregnenolone. Your brain also makes its own pregnenolone locally, where it acts as a neurosteroid in its own right, not just as a precursor.

Most people take it for one of three reasons. As a calming, mood-supporting agent for stress, anxiety, or low-grade depression, particularly in midlife and beyond when levels have dropped sharply. As a cognitive support for memory and mental clarity. Or as an off-label adjunct in conditions like PTSD, chronic pain, and treatment-resistant depression where the clinical evidence is starting to firm up.

How to know if this is for you. The pattern is: over 40, poor or unrefreshing sleep, low mood or stress reactivity, and bloodwork showing serum pregnenolone (LC-MS/MS, not immunoassay) in the lower third of the age-and-sex range, ideally with a low DHEA-S in the same draw. If symptoms and bloodwork line up, it's worth a trial. If your levels are mid-range or higher, the lever isn't there.

If you're on TRT and the honeymoon has worn off, mood, libido, sleep, or sense of wellbeing have flattened out even with T and E2 dialled in, low-dose pregnenolone (10-30 mg) is a reasonable add-on. TRT replaces testosterone but doesn't restore allopregnanolone, which is where pregnenolone's mood and sleep effects actually come from. It won't raise your T further or replace hCG.

When you take oral pregnenolone, most of it doesn't end up as more pregnenolone in your blood. It gets rapidly metabolised, and the biggest downstream pool is allopregnanolone (a GABA-A receptor positive modulator, broadly anxiolytic and calming), with a smaller increase in pregnenolone sulfate. Cortisol and DHEA mostly don't move. So the clinical effect is closer to a mild, slow-acting anxiolytic and mood stabiliser than a testosterone or hormone replacement strategy. Don't expect it to raise your testosterone.

Deep-dive

Pregnenolone is synthesised inside mitochondria from cholesterol via the enzyme P450scc (CYP11A1), which cleaves the cholesterol side chain. This is the rate-limiting and first committed step of all steroidogenesis. From pregnenolone, the body can go two ways: through 3β-HSD to progesterone (then on to cortisol, aldosterone, allopregnanolone), or through 17α-hydroxylase to 17-hydroxypregnenolone and then DHEA (and on to androgens and oestrogens). Your brain, peripheral nerves, and adrenal cortex all do this independently, which is why pregnenolone is sometimes called a neurosteroid: the brain doesn't have to wait for the adrenals to send it material, it can build its own locally inside glial cells and neurons.

Serum pregnenolone peaks in the late teens to mid-30s and then declines progressively, with the drop more pronounced in men than in women. By age 70-75, pregnenolone production is roughly 60% lower than at age 35. The decline tracks closely with DHEA-S since both are made in the zona reticularis of the adrenal cortex. This age curve is part of why pregnenolone is targeted as a replacement strategy in older adults: levels fall, downstream neurosteroids fall, and certain symptoms (low mood, poor sleep, cognitive slowing, anxiety) become more common.

Pharmacokinetics, what oral pregnenolone actually does. Oral pregnenolone has low bioavailability and is rapidly metabolised. The most informative data come from Sripada and Marx's group, who showed that a single 400 mg oral dose triples serum allopregnanolone within 2 hours and roughly triples serum pregnenolone at 3 hours, while DHEA and cortisol levels barely move. In their schizophrenia trial, chronic 500 mg/day dosing raised serum pregnenolone about 4-fold, pregnenolone sulfate about 3-fold, and allopregnanolone about 5-fold. The takeaway: oral pregnenolone is mostly a precursor-loading strategy for allopregnanolone and pregnenolone sulfate, not a way to lift testosterone or cortisol. The therapeutic effects you see in trials are largely GABAergic effects of allopregnanolone plus NMDA modulation by pregnenolone sulfate.

Allopregnanolone, why it matters. Allopregnanolone is one of the most potent endogenous positive allosteric modulators of the GABA-A receptor, meaningfully amplifying GABA's inhibitory effects on neuronal firing. This is the same broad class of action as benzodiazepines or alcohol, but at endogenous concentrations and without the same tolerance and dependence profile. Allopregnanolone has anxiolytic, anticonvulsant, sleep-promoting, and antidepressant effects in animal models, and the synthetic version (brexanolone) is FDA-approved for postpartum depression. Pregnenolone sulfate, the other major metabolite, works on the opposite side: it's a positive allosteric modulator of the NMDA receptor and can enhance learning and memory in animal models. So a single pregnenolone dose pushes both inhibition (via allopregnanolone, GABA-A) and excitation in the right places (via pregnenolone sulfate, NMDA), which is part of why the clinical signal is broader than a pure anxiolytic.

Depression and bipolar depression. This is one of the better-supported uses. In the Brown et al. 2014 randomised controlled trial, 80 adults with bipolar disorder in a depressed state were randomised to pregnenolone titrated to 500 mg/day or placebo for 12 weeks as add-on therapy. Pregnenolone produced significantly greater improvement in depression scores on the Hamilton Rating Scale for Depression and the IDS-SR than placebo, with the effect emerging by week 6. Anxiety scores also improved. There was no increase in manic switching, which is the main worry with antidepressant add-ons in bipolar. An earlier smaller trial in mixed unipolar and bipolar depression at 100 mg/day also showed signal, though was underpowered. Pregnenolone is now being tested for perimenopausal and menopausal depression in multi-site trials, with pilot data showing antidepressant signal in women in the menopausal transition.

Schizophrenia, cognitive and negative symptoms. The Marx et al. 2009 proof-of-concept trial gave 21 stable schizophrenia patients pregnenolone 500 mg/day for 8 weeks as an adjunct to antipsychotics. Pregnenolone significantly reduced negative symptoms (avolition, blunted affect, anhedonia) as measured by the SANS, and serum pregnenolone increases correlated with cognitive improvement on the BACS. The compound was very well tolerated with no effects on weight, blood pressure, glucose, lipids, or prolactin, which is striking in a population usually loaded with antipsychotic side effects. Several follow-up trials have replicated the negative-symptom signal, though effect sizes vary and not every trial has been positive.

Chronic pain. The Naylor et al. 2020 JAMA Network Open RCT randomised 94 veterans with chronic low back pain to pregnenolone (escalated to 500 mg/day) or placebo for 4 weeks as add-on to standard care. Pregnenolone produced a statistically significant reduction in pain intensity compared to placebo, with no serious adverse events. The signal is consistent with prior observational work showing serum allopregnanolone is inversely correlated with chronic pain severity in this population. This is one of the few non-opioid pharmacological signals for chronic back pain that has held up in a properly controlled trial.

PTSD, TBI, and stress disorders. Multiple Phase 2 trials, mostly led by Christine Marx's VA group, have tested pregnenolone in Iraq- and Afghanistan-era veterans with PTSD and mild traumatic brain injury. The rationale is that allopregnanolone is typically reduced in PTSD, and restoring it via precursor loading should help. The early signals are promising but the published data are still incomplete. A neuroimaging study by Sripada et al. showed that a single 400 mg oral dose of pregnenolone in healthy adults reduced amygdala activation and increased connectivity between amygdala and prefrontal cortex during emotion regulation tasks, alongside the expected sevenfold rise in serum allopregnanolone. In plain language: pregnenolone biases the brain toward top-down control of fear and negative emotion, which is exactly the circuit problem in PTSD.

Autism spectrum disorder. A small open-label trial in 12 adults with ASD found that pregnenolone (titrated to 500 mg/day for 12 weeks) reduced irritability and improved some social outcomes, with mostly mild side effects. The trial wasn't placebo-controlled so the signal needs caution, but it points to a broader pattern: conditions characterised by reduced allopregnanolone tend to be the ones where pregnenolone helps.

Cannabis interaction, an unexpected use case. Pregnenolone is a signalling-selective allosteric inhibitor of the CB1 cannabinoid receptor. When THC activates CB1, the brain responds by ramping up endogenous pregnenolone synthesis, which then docks at a distinct allosteric site on the same receptor and blunts the over-activation. Exogenous pregnenolone has been shown to block cannabinoid-induced psychotic-like states in mice and to reduce many of THC's behavioural effects in rodents. This has practical implications: people prone to cannabis-induced anxiety or paranoia, or who use cannabis heavily, may find a pre-dose of pregnenolone takes the edge off. It also means daily cannabis users are already running elevated brain pregnenolone, and supplementation on top may have a smaller marginal effect.

Sleep. Pregnenolone, via allopregnanolone, increases slow-wave deep sleep in EEG studies. Practically, this is consistent with the subjective reports: people on pregnenolone often say their sleep feels deeper rather than longer. It's not a sedative in the way a benzodiazepine is, and dosing it late doesn't reliably put you to sleep. The slow-wave effect is part of the broader GABA-A modulation pattern.

Women. Women have generally higher pregnenolone and allopregnanolone levels than men through the reproductive years, with substantial fluctuation across the menstrual cycle (allopregnanolone tracks progesterone). After menopause, levels drop sharply. The trials that have actually included women throughout (Brown 2014, the autism trial, the ongoing menopausal depression trials) have not shown sex differences in response. If anything, women in the perimenopausal and menopausal transition appear to be among the best responders, since allopregnanolone is implicated in mood disorders specifically in this window. Pregnenolone is being trialled as a non-oestrogen option for menopausal depression precisely because it sidesteps the oestrogen safety concerns of HRT. The flip side is that women with PMDD or premenstrual mood symptoms have a complicated relationship with allopregnanolone, where the issue isn't always too little but rather altered GABA-A receptor sensitivity to it. In PMDD, pregnenolone could go either way and there isn't enough trial data to recommend it confidently in this group.

Older adults. The strongest case for pregnenolone is in adults over 50 with measurably low pregnenolone or allopregnanolone, symptoms in the mood/sleep/cognition cluster, and otherwise good general health. The age-related decline is steep, the downstream consequences are real (lower allopregnanolone is associated with depression, anxiety, and chronic pain), and the side effect profile in clinical trials at this age is unusually clean. If you're going to run this, this is the population where the risk-reward is best.

Limits of the evidence. Most trials are 8-12 weeks, run a few dozen to a few hundred patients, and almost all are in clinical populations (schizophrenia, bipolar, PTSD, chronic pain), not in healthy people looking for an edge. Trials in healthy adults have been small and mostly null on mood or cognition without baseline stress, which suggests pregnenolone works more reliably when something is off than as a general enhancer. Long-term safety data beyond 12-16 weeks is thin. There is no good evidence pregnenolone extends lifespan, prevents cognitive decline, or rebuilds testosterone, despite all three claims being made repeatedly online. The mechanism story for cancer risk (hormone-sensitive tissues) is theoretical and largely untested in long-term human data, but the absence of cortisol or significant androgen elevation in pharmacokinetic studies makes it less worrying than DHEA in this respect.

Dosage:

Low-dose, general mood and sleep support: 10-30 mg/day, oral, in the morning. This is the conservative starting range and what most clinicians who prescribe pregnenolone in private practice use. Start at 10 mg and titrate up over 2-4 weeks based on response and side effects

Mid-range, for measurable low levels with symptoms or for cognitive support: 50-100 mg/day, oral, in the morning. This is the dose most older adults end up at if they need it. Most people get the subjective effect they're after somewhere in this range and don't need to push higher

Clinical trial dose, for depression, schizophrenia adjunct, chronic pain, PTSD: 300-500 mg/day, escalated over 2-4 weeks. This is the dose with the strongest RCT support but it's well above what most people need for general use. If you're targeting a specific diagnosis, this is the range. If you're not, you don't need to be here

Timing: Take in the morning. Pregnenolone has a long enough downstream effect (via allopregnanolone) that evening dosing isn't strictly necessary for sleep benefit, and the alerting/stimulating effect some people report happens often enough that you don't want it interfering with sleep onset

With or without food: Either works. Fat with the dose modestly improves absorption since pregnenolone is lipophilic, but oral bioavailability is poor either way, so don't over-optimise

Sublingual: Some compounding pharmacies and a few supplement brands sell sublingual drops or lozenges. The theory is that bypassing first-pass liver metabolism improves bioavailability. The empirical data here is thin (much of it from clinic-marketed materials rather than published trials), so treat sublingual as plausibly better but not proven. If you're using sublingual, doses are typically much lower (5-15 mg) to match

Cycling: Reasonable to run 8-12 week blocks with a 1-2 week break, especially at higher doses, to reassess whether the effect is still there and to give the HPA axis a reset. Daily indefinite use at 300+ mg has minimal long-term data

Stacks: Pairs naturally with DHEA in older adults where both are low, the two are made in the same tissue and decline together. Pairs with L-theanine, ashwagandha, or magnesium for general anxiety/sleep support without significant interaction concerns. Don't stack with benzodiazepines or other strong GABAergic agents without thought, the additive sedation can creep up

Here's what you can expect:

In the right context (over 40-50, measurably low pregnenolone or allopregnanolone, symptoms of low mood, anxiety, poor sleep quality, or treatment-resistant low-grade depression), you should notice subtle but real improvements in mood baseline, less reactivity to stress, and somewhat deeper sleep within 2-6 weeks. The effect isn't stimulating or dramatic. It's more that the floor of your daily mood and emotional control comes up, anxious thoughts have less grip, and sleep feels more restorative. People often describe it as taking the sharp edges off without sedation.

In the wrong context (young, normal levels, no symptoms, just trying to feel something), you'll probably notice very little. Some people get mild stimulation or a sense of clarity in the first few days that fades. This is the main reason healthy young people abandon it: they took it because the supplement industry sold them on it as an anti-aging or testosterone-boosting strategy, and it's neither.

A reasonable trial is 8-12 weeks at a dose appropriate for your situation. Recheck bloodwork at the end and decide whether it's worth continuing.

Side effects & risks:

Mild stimulation and insomnia are the most commonly reported side effects, especially at doses above 100 mg/day or when dosed in the evening. Move to morning and lower the dose if this happens

Irritability, anxiety, headache, or mood changes in a minority of users. Often resolves with dose reduction. If you feel worse on it after 2-3 weeks, this is your signal to stop, not push through

Acne, oily skin, hair changes can occur at higher doses, more often in women, since some of the pregnenolone load eventually does push through to downstream androgens. Less common and less pronounced than with DHEA but possible

GI discomfort at higher doses (300+ mg). Nausea, loose stools, occasional bloating. Splitting the dose helps

Hormone-sensitive cancers (breast, prostate, ovarian, uterine): pregnenolone is upstream of both oestrogens and androgens, so it's a hard avoid in anyone with current or history of hormone-sensitive cancer, even though the actual conversion to downstream sex hormones at standard doses is modest. Not worth the risk

Endometriosis, uterine fibroids, hormonally-driven gynecological conditions: same logic, avoid unless guided by a specialist who knows your case

Pregnancy and breastfeeding: Skip it. Pregnenolone is upstream of progesterone and the entire reproductive hormone cascade. Safety data in pregnancy is non-existent and the theoretical risk is real

Drug interactions, sedatives: because pregnenolone meaningfully raises allopregnanolone, stacking with benzodiazepines, Z-drugs, alcohol, kava, baclofen, or other GABAergic compounds can produce more sedation than expected. Not necessarily dangerous at standard doses but be aware

Drug interactions, anticonvulsants and antidepressants: generally fine in the controlled trials (where it was tested as add-on to stable medication), but introduce one variable at a time. If you're on an SSRI or anticonvulsant, talk to your prescriber before adding pregnenolone

Bleeding risk: no clear signal, but pregnenolone can affect coagulation factors theoretically through downstream steroid effects. If you're on anticoagulants, run it past your prescriber

Quality control: pregnenolone is sold OTC in the US as a dietary supplement but is prescription-only or unavailable in most of Europe, Canada, Australia, and much of Asia. As with DHEA, independent assays of commercial OTC pregnenolone have historically shown variable content. Use a brand with third-party testing

Long-term safety data is limited. The longest well-controlled trials run 12-16 weeks. Years-long use data don't exist. The signal from short-term trials is unusually clean, but extrapolation has limits

🩸

Blood markers

Pregnenolone (serum, LC-MS/MS): baseline before starting. This is the direct measurement, but be aware that not all labs offer it and immunoassays are unreliable, you want LC-MS/MS. Reference ranges are wide and age- and sex-specific. The goal isn't to push to the top of the range but to confirm you're starting from a low or low-normal baseline before supplementing. Recheck at 8-12 weeks on a stable dose, drawn in the morning before that day's dose.

DHEA-S and total/free testosterone, baseline. Pregnenolone is upstream of both. In men these typically don't move much on standard doses (the conversion isn't efficient), but you want a baseline to know. In women, the androgen response is more variable.

Oestradiol (E2), baseline, especially in men with higher body fat or anyone with breast tenderness, gynecomastia history, or oestrogen-sensitive concerns. Some downstream aromatisation is possible at higher doses.

Progesterone in women, baseline if cycling, since pregnenolone is the direct precursor. Less critical postmenopause.

Cortisol (morning) and DHEA-S to map adrenal function. Pregnenolone doesn't reliably raise cortisol in trial data, but if you're dosing it for adrenal-related fatigue or low-mood symptoms, you want the broader adrenal picture.

Lipid panel and liver enzymes (ALT, AST), baseline if running 100+ mg/day chronically. No specific signal of harm in trials but minimal long-term data.

PSA (men over 40), baseline before starting. Same logic as DHEA, not because pregnenolone causes prostate cancer but because you want a clean reference point.

For most people considering low-dose use (10-30 mg/day) for general mood or sleep support, the minimum useful set is pregnenolone, DHEA-S, total testosterone, and oestradiol at baseline. Anyone running 100+ mg/day chronically should add the full panel above and recheck at 3 months.

Sold OTC as a dietary supplement in the US. Prescription-only or not available in most of Europe, Canada, Australia, and much of the rest of the world.